Skip to main content

Cancer Dx Firm Cernostics Raises $1.4M

NEW YORK (GenomeWeb News) – Cancer diagnostics and prognostics firm Cernostics recently announced it raised $1.4 million in a Series B financing round.

The funds will be used to further develop and commercialize the Pittsburgh-based company's lead product called TissueCypher:Barrett's. Its technology, Cernostics said, quantifies whole slide digital images, providing more information and accuracy than traditional subjective tissue diagnostics and will help eliminate uncertainty around treatment for Barrett's esophagus.

The TissueCypher technology is a digital platform "for multi-channel fluorescence whole slide imaging, and includes image reading, image segmentation, biomarker expression, and tissue structure evaluation," the company said on its website.

Existing investors participating in the Series B round included Novitas Capital, Geisinger Health System, and the Pittsburgh Life Sciences Greenhouse. Cernostics said it has raised more than $6 million since its founding.

Cernostics CEO Mike Hoerres said in a statement that the company has completed early clinical validation for TissueCypher:Barrett's, and the recent funding "enables us to take our next steps towards commercialization, both for our lead Barrett's esophagus product, and the other products in our pipeline."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.